全文获取类型
收费全文 | 3576篇 |
免费 | 375篇 |
国内免费 | 105篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 74篇 |
妇产科学 | 123篇 |
基础医学 | 795篇 |
口腔科学 | 79篇 |
临床医学 | 241篇 |
内科学 | 460篇 |
皮肤病学 | 60篇 |
神经病学 | 468篇 |
特种医学 | 102篇 |
外科学 | 208篇 |
综合类 | 354篇 |
预防医学 | 404篇 |
眼科学 | 28篇 |
药学 | 245篇 |
4篇 | |
中国医学 | 97篇 |
肿瘤学 | 299篇 |
出版年
2024年 | 4篇 |
2023年 | 87篇 |
2022年 | 102篇 |
2021年 | 197篇 |
2020年 | 229篇 |
2019年 | 165篇 |
2018年 | 165篇 |
2017年 | 166篇 |
2016年 | 152篇 |
2015年 | 162篇 |
2014年 | 268篇 |
2013年 | 271篇 |
2012年 | 221篇 |
2011年 | 231篇 |
2010年 | 203篇 |
2009年 | 162篇 |
2008年 | 126篇 |
2007年 | 139篇 |
2006年 | 128篇 |
2005年 | 91篇 |
2004年 | 141篇 |
2003年 | 68篇 |
2002年 | 67篇 |
2001年 | 39篇 |
2000年 | 47篇 |
1999年 | 63篇 |
1998年 | 27篇 |
1997年 | 28篇 |
1996年 | 29篇 |
1995年 | 30篇 |
1994年 | 22篇 |
1993年 | 22篇 |
1992年 | 21篇 |
1991年 | 17篇 |
1990年 | 18篇 |
1989年 | 18篇 |
1988年 | 16篇 |
1987年 | 10篇 |
1986年 | 9篇 |
1985年 | 17篇 |
1984年 | 18篇 |
1983年 | 9篇 |
1982年 | 8篇 |
1981年 | 16篇 |
1980年 | 6篇 |
1979年 | 6篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1973年 | 2篇 |
排序方式: 共有4056条查询结果,搜索用时 31 毫秒
1.
目的:探讨二补助育汤对胚胎着床障碍模型小鼠子宫内膜形态及血管生成素-1(Ang-1)mRNA、血管内皮生长因子(VEGF)mRNA的表达和定位的影响。方法:24只ICR雌性小鼠随机分为空白组、模型组、戊酸雌二醇组、二补助育汤组,每组6只,用米非司酮建立胚胎着床障碍动物模型,各组给予相应药物灌胃,妊娠第5天处死小鼠后,检测各组妊娠率、平均着床位点数、子宫内膜Ang-1和VEGF mRNA表达量及其蛋白定位。结果:模型组小鼠平均胚胎着床位点数、Ang-1 mRNA、VEGF mRNA表达量明显低于空白组(均P<0.05);与模型组比较,二补助育汤组平均胚胎着床位点数、Ang-1 mRNA、VEGF mRNA表达量显著提高(均P<0.05)。结论:二补助育汤可提高子宫内膜Ang-1和VEGF蛋白表达量,促进子宫内膜血管生成,从而提高子宫内膜容受性。 相似文献
2.
Theresa M. Thole Joern Toedling Annika Sprüssel Sebastian Pfeil Larissa Savelyeva David Capper Clemens Messerschmidt Dieter Beule Stefanie Groeneveld-Krentz Cornelia Eckert Guido Gambara Anton G. Henssen Sabine Finkler Johannes H. Schulte Anja Sieber Nils Bluethgen Christian R. A. Regenbrecht Annette Künkele Marco Lodrini Angelika Eggert Hedwig E. Deubzer 《International journal of cancer. Journal international du cancer》2020,146(4):1031-1041
Accurate modeling of intratumor heterogeneity presents a bottleneck against drug testing. Flexibility in a preclinical platform is also desirable to support assessment of different endpoints. We established the model system, OHC-NB1, from a bone marrow metastasis from a patient diagnosed with MYCN-amplified neuroblastoma and performed whole-exome sequencing on the source metastasis and the different models and passages during model development (monolayer cell line, 3D spheroid culture and subcutaneous xenograft tumors propagated in mice). OHC-NB1 harbors a MYCN amplification in double minutes, 1p deletion, 17q gain and diploid karyotype, which persisted in all models. A total of 80–540 single-nucleotide variants (SNVs) was detected in each sample, and comparisons between the source metastasis and models identified 34 of 80 somatic SNVs to be propagated in the models. Clonal reconstruction using the combined copy number and SNV data revealed marked clonal heterogeneity in the originating metastasis, with four clones being reflected in the model systems. The set of OHC-NB1 models represents 43% of somatic SNVs and 23% of the cellularity in the originating metastasis with varying clonal compositions, indicating that heterogeneity is partially preserved in our model system. 相似文献
3.
《European journal of surgical oncology》2020,46(6):982-990
IntroductionLung cancer is the leading cause of cancer-death worldwide. The U.S. Preventative Services Task Force (USPTSF) approved screening for current or former smokers aged 55–80 based on the results of the National Lung Screening trial (NLST). Following the NLST, new evidence has emerged from clinical trials and updates to previous trials prior to the anticipated update to the USPSTF guideline. We review the new evidence on lung cancer screening with low dose computed tomography (LDCT) and the surgical implications.MethodsA review of new literature was performed pertaining to lung cancer screening since implementation of UPSTF guidelines. Articles for inclusion were identified by both authors’, then search of the Pubmed and Cochrane database was performed from January 1st, 2013 through February 4th, 2020 using the MeSH search terms: “lung cancer”; “screening”; “low dose CT”. The results of these studies are summarized.ResultsWe identified multiple prospective randomized control trials and meta-analysis since the NLST supporting lung cancer-specific mortality with screening. We identified new nodule classification systems and the development of risk-models which may reduce false positive rates and identify high risk patients not currently eligible for screening. Finally, we discussed the surgical implications of screening.ConclusionNew data supports NLST findings and show ongoing benefit to LDCT for lung cancer screening. Standardized LDCT screening classification has been shown to reduce harm and lower false positive rates. Further study is needed regarding use of risk-modeling. Screening will require an increase in the thoracic workforce to accommodate the amount of surgically operable cancers. 相似文献
4.
5.
6.
《Clinical neurophysiology》2019,130(9):1465-1473
ObjectiveTo assess the feasibility of motor unit number index (MUNIX) in the quantitative assessment of the cervical spondylotic amyotrophy (CSA).MethodsMUNIX was recorded bilaterally on the abductor pollicis brevis, abductor digiti minimi, biceps brachii and middle deltoid in 41 normal controls and 47 patients with CSA (distal-type to proximal-type ratio: 25 to 22). Additionally, patients were assessed on handgrip strength (HGS), the disabilities of arm, shoulder and hand (DASH) and Medical Research Council (MRC) scales. These examinations were re-evaluated approximately 18 months after surgery in 37 of these CSA patients.ResultsMUNIX values were noticeably lower in the mainly affected muscles of CSA patients than those in controls (P < 0.05), and 49.0% (51/104) of the tested muscles with abnormal MUNIX measurements showed normal muscle strength. Significant correlations between MUNIX measurements and both DASH and MRC scores were observed in both CSA patient groups (P < 0.05). Postoperative longitudinal follow-up analysis identified significant increase in motor unit number in both CSA patient groups within approximately 18 months (P < 0.05), with or without improved measures of motor function.ConclusionsA significant reduction in MUNIX values related to motor impairment was observed in CSA patients, even in the subclinical stage. Compared to measures of motor function, the MUNIX measurements in the patients with CSA improved more noticeably after surgical intervention.SignificanceMUNIX may serve as an available supplementary test to quantitatively evaluate the motor dysfunction in CSA and to track its progression, that is complementary to conventional electromyography. 相似文献
7.
8.
Motor unit number index (MUNIX) in myopathic disorders: Clinical correlations and potential pitfalls
9.
目的:分析子野个数限值对宫颈癌固定野调强放疗(fixed-field intensity-modulated radiotherapy,ff-IMRT)计划的影响,寻求最优的子野个数限值。方法:选取10例接受ff-IMRT的宫颈癌患者,基于Monaco 5.11.03计划系统,以45 Gy/25 f处方剂量分别对同一患者设计8种ff-IMRT计划(ff-IMRT计划依据子野个数限值命名,子野个数限值分别为40、60、70、80、100、120、130、150),采用SPSS 20.0软件比较除plan100之外7个ff-IMRT计划与plan100剂量学参数、优化时间和治疗参数的差异。结果:8种ff-IMRT计划归一化后,plan40和plan60的D2%、Dmin、CI和HI均劣于plan100(P<0.05)。8种ff-IMRT计划均能较好保护危及器官(organ at risk,OAR)和正常组织。plan40小肠V45;plan40和plan60小肠D2cc,直肠、膀胱V45、D40%,两侧股骨头V40和正常组织 V35、V40均高于plan100(P<0.05)。plan40和plan60优化时间、治疗参数均优于plan100(P<0.05);plan120、plan130和plan150子野面积、子野个数(51~150 cm2和>150 cm2)和出束时间均劣于plan100(P<0.05)。结论:子野个数限值为70~100时,ff-IMRT计划能兼顾剂量学参数满足临床要求、优化时间和治疗参数最优化,建议在设计宫颈癌ff-IMRT计划时在该范围内设置子野个数限值。 相似文献
10.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):895-902.e4
PurposeTo study, from a U.S. payer’s perspective, the economic consequences of drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) use for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulae.Materials and MethodsCost differences between DCBs and PTA at year 1 and beyond were calculated via 2 methods. The first approach used the mean absolute number of trial-observed access circuit reinterventions through 12 months (0.65 ± 1.05 vs 1.05 ± 1.18 events per patient for DCBs and PTA, respectively) and projected treatment outcomes to 3 years. The second approach was based on the trial-observed access circuit primary patency rates at 12 months (53.8% vs 32.4%) and calculated the cost difference on the basis of previously published Medicare cost for patients who maintained or did not maintain primary patency. Assumptions regarding DCB device prices were tested in sensitivity analyses, and the numbers needed to treat were calculated.ResultsUsing the absolute number of access circuit reinterventions approach, the DCB strategy resulted in an estimated per-patient savings of $1,632 at 1 year and $4,263 at 3 years before considering the DCB device cost. The access circuit primary patency approach was associated with a per-patient cost savings of $2,152 at 1 year and $3,894 at 2.5 years of follow-up. At the theoretical DCB device reimbursement of $1,800, savings were $1,680 and $2,049 at 2.5 and 3 years, respectively. The one-year NNT of DCB compared to PTA was 2.48.ConclusionsEndovascular therapy for arteriovenous access stenosis with the IN.PACT AV DCB can be expected to be cost-saving if longer follow-up data confirm its clinical effectiveness. 相似文献